Latest Breaking News On - மூல அகிடொ பார்மா இன்க் - Page 2 : comparemela.com

AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer s Disease

AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer s Disease
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesBrett maasUniversity of texas at austinWhile the companyUniversity of maryland at baltimoreAikido pharma incSource aikido pharma incRisk factorsPharma incஒன்றுபட்டது மாநிலங்களில்ப்ரெட் மாஸ்பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் இல் ஆஸ்டின்போது தி நிறுவனம்பல்கலைக்கழகம் ஆஃப் மேரிலாந்து இல் பால்டிமோர்அகிடொ பார்மா இன்க்மூல அகிடொ பார்மா இன்க்

AIkido Pharma Announces Positive Phase 1 Data Presented at ASCO on 225Ac-J591

/PRNewswire/ AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that positive Phase 1 testing data was presented at the 2021 ASCO.

United statesScott tagawaBrett maasUniversity of maryland at baltimoreCarolina urologic research centerAikido pharma incCompany advisory boardSource aikido pharma incWhile the companyUniversity of texas at austinPrnewswire aikido pharma incMeeting juneWeill cornell medicinePharma scientific advisory boardMedical directorAdvisory board

AIkido Pharma Announces Phase 1 Data To Be Presented at the American Society of Clinical Oncology ( ASCO ) Annual Meeting

AIkido Pharma Announces Phase 1 Data To Be Presented at the American Society of Clinical Oncology ( ASCO ) Annual Meeting
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesScott tagawaBrett maasUniversity of texas at austinWhile the companyUniversity of maryland at baltimoreAikido pharma incSource aikido pharma incMeeting juneWeill cornell medicinePharma scientific advisory boardGenitourinary cancerAvailable starting juneRisk factorsPharma incஒன்றுபட்டது மாநிலங்களில்

AIkido Pharma Announces Phase 1 Data To Be Presented at the American Society of Clinical Oncology ( ASCO ) Annual Meeting

AIkido Pharma Inc to Present at the Benzinga Global Small Cap Conference, the Investor Summit Group s Conference, and the LD Micro Invitational Conference

The Company will showcase an updated Investor Presentation and discuss some of its new technology. Darrell Dotson, Vice President and General Counsel, of AIkido Pharma Inc. will present for the Company. About AIkido Pharma Inc. AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may p

United statesDarrell dotsonBrett maasInvestor summit groupUniversity of maryland at baltimoreAikido pharma incSource aikido pharma incWhile the companyUniversity of texas at austinPrnewswire aikido pharma incGlobal small cap conferenceSummit groupInvestor presentationVice presidentGeneral counselRisk factors